REG - Immupharma PLC - Extension of Warrants in Incanthera to 31 Mar 2025

ImmuPharmaAnnouncement

09/09/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI3291Da&default-theme=true

RNS Number : 3291D  Immupharma PLC  09 September 2024

 

 
9 September 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Extension of Warrants in Incanthera to 31 March 2025

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development
company, is pleased to announce that the Company has agreed with Incanthera
plc ("Incanthera") that Warrants issued to the Company on 26 February 2020, in
conjunction with Incanthera's IPO onto the Aquis Exchange, are extended by a
further period to 31 March 2025.

 

Key highlights:

 

·    The Company entered into a Warrant Instrument ("Warrant Instrument")
with Incanthera on 26 February 2020, whereby Incanthera created and issued
Warrants to ImmuPharma to subscribe in cash at 9.5p per share, for 7,272,740
Ordinary Shares, valid until 6 September 2023. On 18 August 2023 Incanthera
agreed with the Company to extend the Warrant Instrument by 12 months to 6
September 2024.

 

·    Incanthera has now agreed with the Company to extend the Warrant
Instrument to 31 March 2025.

 

·    A cash consideration of £75,000 ("Consideration") has been paid by
ImmuPharma to obtain the extension.

 

·    Other than the change in the expiry period, all other provisions in
the Warrant Instrument remain the same.

ImmuPharma currently owns no shares in Incanthera, having sold its previous
holding of c9.9 million shares, as notified on 3 June 2024, at a price of 15p,
realising proceeds of c.£1.5 million for the Company.

 

Tim McCarthy, ImmuPharma's Chairman & CEO, is also the Chairman of
Incanthera and has a holding of 3,931,646 shares in Incanthera (3.36% of
Incanthera's issued share capital).

 

Warrant Extension Rationale

 

ImmuPharma's rationale for agreeing to pay the Consideration to secure the
extension of the Warrant Instrument is based on the following fundamental
criteria:

 

·    As at close of business on 6 September 2024, Incanthera's mid-market
share price was 28.5p, which demonstrates a current nominal "in the money"
value of the warrants of 19p per share, equivalent to £1.38 million.

 

·    ImmuPharma's Board believes that the Incanthera investment case is
robust and that there is potential for a further accretive share price, based
on key milestones being met over the next period to 31 March 2025.

 

·    As reported in ImmuPharma's Interim results (which were also
announced today), the Company has continued to manage its operations in a cost
efficient manner and with a cash balance of £1.1m of cash as at 30 June 2024,
the Company has a robust cash runway moving forward. However, the Board did
not feel it would be prudent to have deployed c£691k of the Company's funds
in exercising the Warrant in the period ended 6 September 2024 (the end of the
previous expiry period). This prudent control of cash reserves needs to
continue over the next period.

 

·    As also reported in the Interims, ImmuPharma continues to concentrate
on securing further commercial and partnering deals over the next period, that
could potentially provide a significant cash injection into the Company, to
allow the Warrants to be exercised in full, and allow the Company to restore a
c. 6% shareholding in Incanthera.

 

Related Party Transaction

 

The extension of the Warrants has been treated as a related party transaction
under the AIM Rules for Companies. Mr. McCarthy has not been involved in the
Board decision in respect to agreeing to the terms of the extension.

 

The Directors (excluding Mr. McCarthy), having consulted with SPARK, the
Company's nominated adviser, consider that the terms of the Warrant extension
are fair and reasonable insofar as the Company's shareholders are concerned.

 

Commenting on this announcement, Tim Franklin, COO of ImmuPharma said: "After
careful consideration, we believe an investment of £75k, to secure extended
optionality associated with the warrant extension, not only retains the
nominal "in the money" value in the Warrants, but also allows us to benefit
potentially from any further accretion in Incanthera's share price as they
meet key milestones over the next period."

 

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim Franklin, Chief Operating Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFETAEITIIS